Needham Reiterates Buy on Generation Bio, Maintains $15 Price Target

Generation Bio Inc., formerly Generation Bio Co., is a biotechnology company. The Company is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. It focuses on targets in T cells that are undruggable or poorly drugged. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.